Vaxcyte's pneumococcal vaccine succeeds in Phase 3, stock surges
Phase 3positiveVAX-31Positive
AI Analysis
Summary
Vaxcyte's pneumococcal vaccine VAX-31 met key endpoints in a Phase 3 trial with adults, driving a 35% stock surge. The positive result represents a major milestone for the company's vaccine development program.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Met key endpoints in Phase 3 trial with adults
Importance:8/10
Sentiment:
0.90
pneumococcal vaccinePhase 3 successstock surge
Related Companies
Read the original article
Published by Endpoints News on October 5, 2026 3:06 PM